Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
INTRODUCTION
The treatment of multiple myeloma (MM) has remarkably changed in the past 10 years, and subsequently the role of allogeneic stem cell transplantation (allo-SCT) has been amended over time.
Despite the dramatic recent advances, allo-SCT is still regarded as the only potential cure on account of its well-documented graft-vs.-myeloma (GvM) (1-4) . However, the introduction of new compounds capable of inducing high response rates with limited side effects (5-7), has greatly challenged its role, although recent retrospective reports have shown that their use and GvM effect are not mutually exclusive and a strong synergistic effect may be established (8) . What is, therefore, the actual role of allo-SCT in MM? Currents efforts aim at defining its role in combination with new drugs in the light of patient risk factors and their impact on clinical outcomes. Clinical trials are in progress in newly diagnosed high risk patients and in early relapses.
Future perspectives are challenging: firstly, the worldwide introduction of new generation immunomodulatory drugs (IMiDs) and proteasome inhibitors may help consolidate disease response after allo-SCT and, secondly, even prevent graft-vs.-host disease (GvHD). In this report, we will examine the latest observations on novel agents such as Thalidomide (Thal), Bortezomib (Bor) and Lenalidomide (Len) in GvHD prevention and treatment. Then, given the growing interest in the evaluation of minimal residual disease (MRD) in haematological malignancies, we will overview its role after allo-SCT as a prognostic factor. Finally, we will explore the new promising frontier of chimeric antigen receptor (CAR) -T and -NK cells where the post-allo-SCT microenvironment may be attractive for adoptive immunotherapies.
ALLOGRAFTING IN MULTIPLE MYELOMA
The GvM effect has been well documented in the past two decades, primarily by the capability of donor lymphocyte infusions (DLI) of inducing remission in MM patients relapsed after an allograft (2, 3, 9, 10) . Indirect evidence of GvM effects was also provided by Bjorkstrand et al. who showed a higher relapse/progression rate in auto-SCT as compared with allo-SCT recipients in a series of 189 patients (11). Furthermore, though similar the intensity of the conditioning regimen, molecular remissions appear to be more frequent after myeloablative allo-SCT than after auto-SCT, predicting better overall survival (OS) and event-free survival (EFS) (12, 13).
Recently, Binsfeld et al. (14) described the establishment of a reliable GvM model using allo-SCT in immunocompetent tumor-bearing mice. In this model, effector memory CD4 and CD8 T cells were shown to affect the in vivo GvM effect, with CD8 T cells playing a pivotal role. Within CD4 and CD8 subsets, the Authors identified overlapping TCR-Vb families that reacted against both myeloma cells (anti-tumor) and Balb/cJ cells (alloreactive), underlining the relationship between anti-tumor responses and GvHD. However, some TCR-Vb families within CD4 T cells specifically reacted either against myeloma or host alloantigens. This model may help to investigate in future studies mechanism of IMiDs and their impact on the balance between GvM and GvHost effects.
Despite the curative potential, myeloablative allo-SCT is hampered by a remarkable incidence of transplant related mortality (TRM), the most controversial aspect on its role in MM. To lower TRM, reduced intensity conditioning (RIC) regimens, more immunosuppressive rather than cytoreductive, were explored, primarily in the light of the Seattle experience (15, 16, 17) ( Figure 1 ).
Bensinger et al. recently reported the long-term outcomes of 278 patients treated with allo-SCT
after myeloablative conditioning (MAC) (N=144) or RIC/non myeloablative (N=134) regimens.
The latter resulted in significantly lower overall mortality (hazard ratio [HR] 0.40, p<0.0001) with far lower TRM (HR 0.22, p< 0.0001) and improved progression free survival (PFS) (HR 0.55, p= 0.0002). Interestingly, the risk of relapse/progression was not significantly different in Cox models between MAC and RIC/non myeloablative conditionings (18).
Given the importance of pre-allo-SCT cytoreduction had been widely recognized, the combination of auto followed by allo-SCT with RIC was also investigated in newly diagnosed patients. Recent results reported a TRM of 11% at 1 year, and, after a median follow-up of at least 5 years, a median OS and PFS not reached and of 35 months, respectively (19, 20) .
Despite the introduction of the so called "new drugs", single or double auto-SCT remains part of standard upfront treatment in patients up to the age of 65 (21-24), whereas the upfront use of RIC allo-SCT has practically been abandoned and remains undefined.
Only few randomized trials, based on donor availability, compared tandem auto-SCT versus tandem auto/RIC allo-SCT. Importantly, all these trials were designed before "new drugs" became readily available.
An Italian randomized trial showed improvement in PFS and OS in the auto/allo-SCT group (8, 25) . After a median follow-up of 7 years, median OS was not reached (p= 0.02) and EFS was 39 months (p= 0.02) in the 58 patients who received tandem auto/allo-SCT, whereas OS of 5.3 years and EFS of 33 months were observed in the 46 who received two auto-SCT. The plateau in OS curve suggests a possible curative effect of RIC allo-SCT in a subgroup of patients.
By contrast, the randomized BMT CTN 0102 phase III trial enrolled 710 patients from Centers across the United States (26) . Patients with a HLA-identical sibling received a RIC allo-SCT as part of planned tandem auto/allo-SCT. The study showed no difference in OS (77% versus 80%) or PFS (43% versus 46%) between the auto/allo-SCT group and the tandem auto-SCT group at three years. Group for Blood and Marrow Transplantation (EBMT)-NMAM-2000 study that prospectively compared tandem auto/RIC allo-SCT versus single auto-SCT. Three-hundred-fifty-seven patients up to age 69 years were enrolled. Patients with a HLA-identical sibling were allocated to the auto/RIC allo arm and those without to the single auto-SCT arm. Progression-free survival and OS were 22% and 49% versus 12% (p= .027) and 36% (p= .030) in the auto/RIC allo and in the auto-SCT groups, respectively. Corresponding relapse/progression rates were 60% versus 82% (p= .0002). Transplant related mortality at 36 months was 13% vs 3% (p= .0004). The importance of long-term follow-up for the correct evaluation of auto/RIC allo versus auto-SCT studies was clearly demonstrated in this study as survival curves between the 2 groups started separating about 3 years post-transplant. high dose melphalan and auto-SCT followed by maintenance therapy, whereas those with a donor were intended to receive a planned auto/allo-SCT following a non-myeloablative conditioning. In a first intention to treat analysis, donor availability was not associated with better clinical outcomes and there was no benefit in patients treated with upfront tandem auto/allo-SCT. However, given that a considerable number of patients with a donor were not eventually transplanted, the analysis may have underestimated the potential benefit of the allograft. The same study group (33) recently expanded the statistical analyses by evaluating the allo-SCT as a time dependent variable and by carrying out a landmark analysis. By comparing the different methods, it was shown that the efficacy of allo-SCT was underestimated by a donor versus no donor analysis, whereas the use of both the allo-SCT as a time dependent analysis and a landmark analysis may more reliably evaluate its impact in newly diagnosed patients. In the experience on high risk patients by the Intergroup Françophone du Myélome (IFM), after a median follow-up of 56 months, no differences in EFS were observed and there was a trend toward a better OS in the double auto-SCT group as compared with the auto/allo-SCT group (48 vs. 34 months, p= 0.07) (34, 35). In a Spanish trial, only patients who failed to achieve complete remission (CR) or near CR after the first auto-SCT were eligible for the second transplant. Authors showed a trend toward a better PFS (p= 0.08) in 25 patients treated with tandem auto/allo as compared with 85 patients who received double auto-SCT, with a plateau of PFS in patients in CR after tandem auto/allo-SCT. However, this did not translate into a significant advantage in OS after a relatively short follow-up (36).
Knop et al. presented results of a German study which investigated the impact of del(13q) (37).
Patients received either a planned double auto-SCT or an upfront auto followed by an allo-SCT.
The study included 199 patients with a median age of 53 years. Seventy-three patients received the double auto-SCT, whereas the remaining 126 received tandem auto/allo-SCT. The study showed that patients with del(13q) may benefit from the auto/allo-SCT approach. After a median follow-up up of 7.6 years, auto/allo-SCT group had significantly longer median PFS than the double auto-SCT group (34.5 and 21.8 months, respectively). The benefit in PFS was independent of donor type (matched related or matched unrelated donor). Median OS did not significantly differ between the two treatment groups (71.8 months for double auto-SCT and 70.2 months for auto/allo-SCT patients). Two-year NRM was 12% in the auto/allo and 4% in the double auto-SCT group.
Hofmann et al. reported a retrospective analysis on 95 allo-SCT patients treated between 1994 and 2013 at Ulm University Hospital (38). Cytogenetic abnormalities did not affect PFS and OS.
Overall survival was significantly better in patients who did not develop acute GvHD, whereas chronic GvHD had no impact on clinical outcomes. Patients who received a myeloablative conditioning showed a trend for lower relapse as compared with those who received a RIC. Acute GvHD was associated with poorer OS and PFS, whereas chronic GvHD with better clinical outcomes suggesting an important role for the GvM effect.
Overall, results of comparative studies have been rather conflicting, probably due to small numbers and heterogeneity in patients characteristics. Recent meta-analyses that included studies on tandem double auto and tandem auto/allo-SCT in newly diagnosed patients were published. One study included 1538 patients. Despite higher CR rates, the meta-analysis did not show any improvement in OS and EFS with the auto/allo-SCT. The Authors suggested the use of an allo-SCT only in the context of clinical trials (40). Importantly, at the time these studies were designed, no risk assessment at diagnosis was routinely possible. In another meta-analysis, (41), the Authors included 6 trials for a total of 1192 patients in the double auto and 630 in the auto/allo SCT group.
Patients in the latter group had a higher chance of reaching CR that did not however translated in better OS at 3 years from treatment assignment because of higher TRM. An updated meta-analysis with longer follow up is in progress.
NEW DRUGS AND ALLOGRAFTING IN MULTIPLE MYELOMA
The advances in the understanding of the pathophysiology of MM culminated in the development of smart drugs that target specific intracellular pathways and the crosstalk between clonal plasma cells and the microenvironment. Clinical trials showed potent activity in first-line and in salvage treatments in relapse/refractory disease (5-7, 42-46).
In the light of these findings, further strategies have been developed to explore feasibility 
Is there any evidence of a synergy between donor T cells and new drugs?

Allografting and "new drugs" as maintenance
To improve clinical outcomes of allo-SCT as part of first-line treatment, the role of Len maintenance was investigated. The first study reported on 30 patients, who started Len from 1 to 6 months after a non-myeloablative allo-SCT. Lenalidomide was administered on a 10 mg daily schedule 21 out of 28 day cycles. Responses were observed in 37% of patients, but the main limit was drug discontinuation due to flare of GvHD in 43% (13) patients. Furthermore, 5 patients (17%)
stopped Len maintenance because of other adverse events and 5 after disease progression (50). EMatologiche dell'Adulto (GIMEMA) (NCT01264315); a phase II multicenter study of the new proteasome inhibitor MLN9708 (NCT2168101). Finally, a phase II prospective safety study on Len maintenance in high risk population was recently closed (NCT00847639) and results will be available soon.
Allografting and "new drugs" as salvage therapy (Table 1)
The long term follow up of a prospective Italian study comparing double auto vs. auto/allo-SCT in newly diagnosed patients allowed to formulate suggestive hypothesis. Among relapsed patients, the "allo-group" rescued with Thal, Len or Bor showed a significantly better median OS from the start of salvage therapy as compared with the "double auto-group" (not reached vs. 1.7 years, p= 0.01) (8). This finding may partly be explained firstly by a synergy between the high percentage of donor T cells, usually seen at relapse after a non-myeloablative allo-SCT, and IMiDs that may help to restore GvM, and secondly, that donor T cells may favour the anti-MM effect of new drugs in the marrow milieu.
Other groups also reported interesting data. The efficacy and safety of Thal in relapsed/refractory patients after allo-SCT was retrospectively evaluated only in few small cohorts without very promising results (54-57). An interesting experience comes from the IFM group. An overall response rate (ORR) of 29% without CR was reported in 31 patients enrolled in a multicenter trial. Thal was discontinued in 19% because of neurological toxicity (54).
Bortezomib was employed in more trials. In a retrospective cohort of 37 patients, peripheral neuropathy, mild thrombocytopenia and fatigue were the most frequent adverse events. However, Overall, despite the limitation of retrospective studies, Len appears to be the most promising drug as salvage after allo-SCT enforcing the hypothesis that Len enhances GvM by interacting with donor T cells (67-69). Unfortunately, the potential survival benefit may be outweighed by its side effects. In particular, the risk of GvHD should be considered as a major issue if Len is administered early after allo-SCT. GvHD are though to be triggered by the same allo-reactive T cells of donor origin that underline the curative potential of GvM effect. In fact, efforts to reduce the incidence of GvHD by in vivo or preinfusion T cell depletions have also been associated with diminished responses and higher relapse rates. The role of IMiDs and proteasome inhibitors in prevention and treatment of GvHD, while sparing GvM effect, has been investigated with some interesting results summarized below.
Thalidomide
Preclinical studies demonstrated the Thal is characterized by many immunological effects such as the reduction of TNF-alpha levels, inhibition of IL-1, IL-6, IL-12 production, co-stimulation of IL-2 and IFN-gamma producing T cells, and down-regulation of adhesion molecules involved in leukocyte migration and angiogenesis (71, 72). Thal was also employed in few studies for the treatment of chronic GvHD. The ORR varied and primarily observed in oral and skin GvHD (73-76). However, in some experiences, a remarkable drug discontinuation rate up to 90% was reported due to haematological and neurological toxicities (77, 78). Thal is currently only rarely used in refractory chronic GvHD and specifically in muco-cutaneous manifestations (72).
Lenalidomide and pomalidomide
As previously described, some issues on Len feasibility, used as maintenance/consolidation therapy after allo-SCT, have emerged regarding its early administration post-transplant and excessive flare of GvHD (50, 51). Linhares et al. assert that some trials may also have been conducted but not reported because of negative results, determining a publication bias (79).
The novel IMiD pomalidomide (Pom), 100-fold more potent than its parent compound, was evaluated in a small pilot study on steroid refractory cGvHD. Only 3/8 patients completed the 6 month treatment. Two/3 achieved complete and 1/3 partial responses. The remaining 5/8 patients discontinued the drug for absence of response or toxicity (80). A larger randomized phase II trial of Pom in refractory cGvHD patients is currently in progress (NCT01688466).
Histone deacetylase inhibitors and Carfilzomib
Interesting preclinical data are emerging on Histone deacetylase inhibitors (HDACis) and
GvHD. The Results are not yet available (NCT00815919).
In summary, preliminary data suggest a possible role of new drugs other than Len in GvHD prevention or second line treatment. Furthermore this technique can be successful in less than 80% of patients (12, 13, 102, 103) . In this study, the Authors showed, in 15 auto and 14 allo-SCT patients with a molecular marker, a higher proportion of PCR-negative remissions after allo-SCT rather than auto-SCT (50 vs. 7%) that Table 2 .
Allografting and minimal residual disease
In summary, MRD assessment seems to have a role in predicting outcome after MM standard treatment as well as Allo-SCT and its evaluation should be included in future prospective trials.
CHIMERIC ANTIGEN RECEPTORS IMMUNOTHERAPY in MM
The potential efficacy of cellular therapies in MM is highlighted by the observation that allo-SCT and donor lymphocyte infusions had been associated with disease response due to GVM effect. Novel strategies designed to obtain a specific immune response decreasing the immune- 
Expert opinion
The growing impetus for developing modern cell immuno-therapies largely stems from clinical observations that allo-SCT is curative in a variety of hematological diseases. Initially conceived as a mere rescue strategy after myeloablative doses of chemotherapy, it is now clear that the donor immune system transferred into the recipient may highly contribute to disease eradication given its immunological driven anti-tumor effects.
In MM, high TRM and limited efficacy in long-term disease control have so far prevented the demonstration of a clear benefit of all-SCT (17 The use of bortezomib within the conditioning may prevent GvHD, given its ability to eradicate alloreactive T cells, and limit the risk of relapse after RIC allo -SCT (86, 90, 129-131) .
Bortezomib may potentially be associated also with DLI where, though an extensive application, a CR rate of less than 30% and a close association between anti-myeloma responses and GvHD have been reported (130). Recently, Alsina et al. also showed that a lower dose of Len after allo-SCT is feasible and could represent a strategy of maintenance therapy as similar to that used in the post auto-SCT setting (53). The development of novel immunotherapeutic strategies may further support research programs that target specific disease antigens with cell therapies (131). More recently, MM has offered several appealing targets for the development of vaccines and CAR-based immunotherapies that may potentially be well combined with current treatments.
In conclusion, we think that allo-SCT conserves a role in MM and its curative potential in high risk patients should be explored in the setting of control clinical trials. Moreover, novel cell therapies such as CAR technologies may open new avenues of research toward a potential cure.
Data from currently ongoing prospective studies will be helpful to clarify pending clinical questions.
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